Clinical trial
A First in Human, Single Center, Single Dose, Randomized, Placebo-controlled, Dose, Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ENT-03S for the Treatment of Obesity and Diabetes
NCT05925920 is registered in ClinicalTrials.gov with Metabolics Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A First in Human, Single Center, Single Dose, Randomized, Placebo-controlled, Dose, Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ENT-03S for the Treatment of Obesity and Diabetes
- Lead sponsor
- Metabolics Pharma
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 13, 2023
- Completion date
- August 12, 2024
- Enrollment
- 49 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.